
    
      This study is a two-part study. Part A is double-blind, placebo-controlled, and will examine
      the safety and PK profiles of multiple doses of LT3001 drug product in healthy subjects. Part
      B is open-label and will assess the safety and PK of LT3001 when coadministered with aspirin,
      clopidogrel, apixaban or dabigatran.
    
  